WO2000030578A1 - Traitement enzymatique et prevention des hypertrophies cutanees - Google Patents

Traitement enzymatique et prevention des hypertrophies cutanees Download PDF

Info

Publication number
WO2000030578A1
WO2000030578A1 PCT/IL1999/000629 IL9900629W WO0030578A1 WO 2000030578 A1 WO2000030578 A1 WO 2000030578A1 IL 9900629 W IL9900629 W IL 9900629W WO 0030578 A1 WO0030578 A1 WO 0030578A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
carrier
layer
dressing
skin
Prior art date
Application number
PCT/IL1999/000629
Other languages
English (en)
Inventor
Tatyana Elbakyan
Original Assignee
Bio-Silk Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio-Silk Ltd. filed Critical Bio-Silk Ltd.
Priority to EP99956303A priority Critical patent/EP1152723A1/fr
Priority to JP2000583463A priority patent/JP2003517448A/ja
Priority to AU12934/00A priority patent/AU1293400A/en
Publication of WO2000030578A1 publication Critical patent/WO2000030578A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Definitions

  • the present invention relates to a topical therapeutic composition, a dressing including it and use of enzymes in its manufacture.
  • Wounds may be defined as damage to the skin, and may be caused by a scratch, heat, cold, chemical or radioactive substances, electricity, etc.
  • the term "wound” includes burns and scars.
  • the skin is one of the most important sensory organs in the body arid it is the body's defensive mechanism against the environment. When part of the skin is damaged, water, salts, proteins and energy are liable to be leaked out of the body through the damaged skin. Fungi and bacteria may cause local infection in the wound, with the threat of deeper penetration into the body, resulting in substantial inflammation.
  • the purpose of treating wounds is to repair the damage caused to the skin. If the damage is restricted and local, cure will usually take a few days, or perhaps weeks. However, if the damaged area is extensive and severe, the curing process will be slow and skin implantation and other treatments, e.g. drug administration, may well be essential. Often, curing wounds involves severe pain, leaves scars and requires physiotherapy and/or psychological treatment; in severe cases the treatment will have to deal with such problems as bleeding, contamination, pains, poisons, water accumulation, etc.
  • native enzymes to treat wounds are quite common.
  • These enzymatic preparations are generally based on e.g. proteolytic enzymes such as trypsin and chymotrypsin (which cleanse purulent-necrotic wounds and reduce the amount of pathogens), lysozyme (which dissolves bacteria cell walls), and/or coliagenase (which decomposes collagen and prevents formation of rough scars).
  • Enzymatic preparations usually take the form of gels, powders or liquids, which are spread on the wounds.
  • native proteolytic enzymes to treat wounds is quite common. However, this method suffers from some major shortcomings, e.g. native enzymes are rapidly inactivated by inhibitors, they are unstable in aqueous solutions, exhibit antigen and pyrogen properties, may penetrate into blood circulation and give rise to an allergic reaction, besides being relatively expensive.
  • a method for treating wounds is based on covalent binding of bioactive reagents, e.g. proteolytic enzymes, onto dialdehyde cellulose dressings and/or aldehyde polycaproamide dressings.
  • bioactive reagents e.g. proteolytic enzymes
  • dialdehyde cellulose dressings and/or aldehyde polycaproamide dressings Exemplary of such dressings are those formed by acid hydrolysis of polycaproamide, followed by reaction of glutaraldehyde with terminal amino groups in the hydrolysate.
  • Immobilized enzyme dressings of this type solved the problem of the previous polyaldehyde beads (i.e. they tend to be removed from the wounds by liquid flowing therefrom), but apparently still did not solve other problems such as leakage of bound enzymes into the body liquid and poor mechanical properties.
  • the protein collagen is important in the wound healing process.
  • wounds whether accidental or intentional (e.g. resulting from surgery), often give rise in the healing stages to what appears to be a random accumulation of tissue rich in collagen and proteoglycan.
  • Keloids are tumors which occur in the dermis, usually following trauma, and they often recur after surgical removal.
  • Hypertrophic scars are tissue accumulations, frequently disfiguring, the removal of which is problematic.
  • Depressed scars result from contraction of the skin (e.g., in normal healing following inflammatory acne); they are usually both permanent and unsightly.
  • Acne vulgaris often causes undesirable scarring.
  • Post-surgical adhesions which are a common complication of surgery, and also wrinkling, cellulite formation and neoplastic fibrosis, appear to involve excessive collagen formation.
  • hypertrophic skin accumulations For convenience, undesired hypertrophic accumulations of collagen such as are described in the preceding paragraph, will be referred to collectively herein as "hypertrophic skin accumulations".
  • Their dissolution or prevention by administration of coliagenase and optionally also hyaluronidase, directly into the lesion or the affected area, in practice by injection, is described for example in U.S. 4,524,065; see also, Friedman, K., et al., Brit. J. Dermatol., 1986, 115: 403-8.
  • U.S. 5,516,673 describes a process for conjugating, i.e. covalently bonding, an amino compound such as an enzyme, to a polyhydroxy-polymer such as cellulose, other polysaccharide, or polyvinyl alcohol
  • the enzyme may be e.g. trypsin, chymotrypsin, lysozyme, coliagenase or hyaluronidase, and the polymer may be in the form of a bandage or patch, which finds utility in the treatment of wounds, including scars and bums.
  • the polymer or its functional derivative is conjugated with cross-linked biologically active protein, e.g. an enzyme.
  • the product may take the form of a powder, bandage or patch, for application to wounds, including bums and scars.
  • US 4,399,123 describes a product made by treating mammalian fibrous tissue with proteolytic enzyme (I) and then with a carbohydrate-splitting enzyme (II) (e.g. amylase, hyaluronidase or neuramidinase).
  • I proteolytic enzyme
  • II carbohydrate-splitting enzyme
  • the product is used as skin tissue transplantation for permanent repair or as a temporary dressing for cutaneous wounds and soft tissue injuries.
  • DE 3139089 describes use of proteinaceous (e.g. collagen) sheets as carriers for therapeutically active non-immobilized enzymes for application to the skin including wound dressings.
  • the sheets may contain hyaluronidase in combination with therapeutically active substances.
  • scars are treated by covering with a thermal insulating material, possibly containing a medicament such as a calcium antagonist, in order to elevate the surface temperature of the scar, and thus stimulate coliagenase activity therein.
  • a thermal insulating material possibly containing a medicament such as a calcium antagonist
  • Exemplary of numerous skin- or bum-treating compositions is that of US 4,154,823, which comprises p-aminobenzoic acid, Ca d-pantothenate and ⁇ -tocopherol, and optionally aloe, Kava Kava and/or methyl salicylate.
  • Another general object of the invention is to provide such a composition characterized by the absence of covalent bonding between the carrier and the therapeutically active substance(s).
  • a still further general object of the invention is to provide such a composition for topical administration, characterized by the fact that release of active substance to the desired locus of treatment is initiated and regulated by the action of moisture in the skin.
  • Yet a further general object of the present invention relates to use of enzymes (and optionally other therapeutically active and/or other skin treating ingredients) in the manufacture of a slow-release therapeutic composition for prevention and treatment of hypertrophic skin accumulations.
  • an object of the present invention to provide a slow-release therapeutic composition for topical administration in the prevention and treatment of hypertrophic skin accumulations.
  • a further object of the present invention is to provide an enzymatic composition having the mentioned characteristics.
  • Another object of the invention is to provide such a composition in the form of a thin layer or film.
  • Still an additional object of the invention is to provide a composition of the type mentioned which may be used also for skin treatment following a cosmetic skin operation.
  • the present invention accordingly provides a dressing for topical application in the prevention and treatment of hypertrophic skin accumulations and which possesses sufficient flexibility and coherence, such that it can be produced in rolls or sheets, from which portions may be cut to a desired size, which dressing consists of or comprises, a layer or film of a water soluble composition comprising, and designed for slow release of, at least one active ingredient selected from coliagenase and hyaluronidase, in admixture with at least one carrier which comprises at least one biocompatible cold water soluble polymer.
  • slow-release in the present specification and claims means slow release of therapeutically active substance(s) from the said water soluble composition.
  • the present invention provides use of at least one enzyme selected from coliagenase and hyaluronidase, in admixture with at least one water soluble carrier composition which comprises at least one biocompatible cold water soluble polymer, in the manufacture of a dressing for topical application which includes said composition in the form of a layer or film, for slow release of said enzyme in treatment of hypertrophic skin accumulations and in the healing process of wounds and burns, excluding open wounds, provided that said dressing possesses sufficient flexibility and coherence, so that it can be produced in rolls or sheets, from which portions may be cut to a desired size.
  • polymer in the present specification and claims includes both homopolymers and copolymers.
  • Figure 1 is a sectional depiction of an embodiment of the invention
  • Figure 2 is a depiction in plan of a different embodiment of the invention.
  • the therapeutic composition useful in the invention is preferably further characterized by at least one of the following features: (a) the carrier is a tacky carrier; (b) the composition comprises additionally a pharmaceutically acceptable antioxidant, e.g. at least one vitamin selected from vitamins C and E; (c) the polymer contains repeating units containing at least one function selected from alcoholic, ether and ketonic functions, e.g.
  • composition incorporates at least one further therapeutically active and/or other skin treating ingredient; (e) the composition contains a biocompatible water-soluble plasticizer, e.g., glycerol or low MW polyethylene glycol. It is believed that vitamin C and/or E may act beneficially with regard to skin metabolism, in addition to their antioxidant activity.
  • the further therapeutically active and/or skin treating ingredient(s) may be exemplified by a steroidal antiinflammatory agent, such as prednisolone or triamcinolone acetonide and/or a non-steroidal such agent, e.g. a scopolamine derivative, for example anisodine, or e.g. any of the ingredients (therapeutically active or otherwise, taken alone or in any combination) specified in US 4,154,823.
  • a steroidal antiinflammatory agent such as prednisolone or triamcinolone acetonide
  • a non-steroidal such agent e.g. a scopolamine derivative, for example anisodine, or e.g. any of the ingredients (therapeutically active or otherwise, taken alone or in any combination) specified in US 4,154,823.
  • the present compositions are characterized inter alia by the absence of covalent bonding between the carrier and the therapeutically active substance(s).
  • the immobilization of the enzymes in these patents is believed to be contrary to what is desirable in the treatment of hypertrophic skin accumulations, as being liable to reduce the activity of active sites in the enzyme and to prevent mobility, whereas mobility is considered advantageous, in the present context.
  • the invention in one aspect relates to a dressing for topical application in the prevention and treatment of hypertrophic skin accumulations.
  • the dressing may be configured as a patch of laminar construction comprising an absorbent layer supporting at least one thin layer of the composition, adhered to a non-absorbent backing layer, and being covered by a thin peelable protective layer, wherein the absorbent layer may optionally contain the composition.
  • a plurality of therapeutically active and/or other skin-treating ingredients and/or vitamin C and/or E, when present, may be located in the same layer or film, and/or in different adjacent layers or films.
  • High purity lyophilized coliagenase (typically Sigma C0773) is thoroughly mixed with cold water soluble polyvinyl alcohol (Sigma P8136), such that the mixture contained per ml, 500, 750 or 1000 units coliagenase.
  • Salt-free lyophilized hyaluronidase (typically Sigma H3884) is thoroughly mixed with cold water soluble polyvinyl alcohol (Sigma P8136), such that the mixture contained per ml, 500, 750 or 1000 units hyaluronidase.
  • Examples 1 and 2 are mixed in such ratios that the resultant mixture contained per ml, either 250 or 500 units coliagenase, together with 375 units hyaluronidase. Since release of the active ingredient(s) from the admixture with carrier is to be initiated and maintained by skin moisture at the locus of application, it is desirable to store the compositions of the invention, as well as any dressings containing them, before use, in a moisture-free atmosphere. Administration of the compositions of the invention
  • the present invention is not directed to the treatment of open wounds. Rather, it is concerned with preventing scar and keloid formation in circumstances where they are expected to be formed, i.e. during the healing process of e.g. wounds and burns, as well as with treating hypertrophic skin accumulations already formed.
  • the present invention enables amelioration of hypertrophic accumulations in connective tissue, or prevention of their formation.
  • composition of the invention may be, in a particular embodiment, configured as a single layer or multilayer dressing.
  • he composition may be (as a single layer or multilayer) supported on a dressing, which is then applied to the desired locus on the skin.
  • the compositions may be utilized in the form of patches, e.g. as Illustrated in section in Fig. 1 , which shows a laminar construction (in which the individual layers 2, 4, 6 and 8 are not necessarily drawn to scale), comprising an absorbent layer 4 supporting a thin layer 6 of the inventive composition, and adhered to a non-absorbent backing layer 2, while covered by a thin peelable layer 8, which is removed immediately before use. It will be evident that many variations of this arrangement are possible, e.g.
  • absorbent layer 4 may contain and act as a reservoir for the composition, or alternatively layer 4 may be dispensed with altogether, the composition then being supported on backing layer 2, but still being protected, if desired for many practical purposes, by peelable layer 8.
  • layer 4 may instead represent a further polymeric layer containing e.g. vitamin C or E, and/or a further therapeutically active and/or other skin treating ingredient such as at least one steroidal or non-steroidal antiinflammatory agent. in the healing of face burns, and in which the individual items shown are not necessarily drawn to scale.
  • Mask 12 has holes or slits as necessary, for the eyes 14, nostrils 16 and mouth 18.
  • composition of the invention will in a particular embodiment be supported on that side of mask 12 to be applied to the face of a patient, while in a different embodiment the mask will be constituted by a self-supporting single or multi-layer or film of the inventive composition. It will be evident that many variations in the shape and size of such a mask, and of the holes or slits shown therein, are possible.
  • the mask may have a laminar arrangement in the manner illustrated in Fig. 1. Alternatively, the mask may be constructed as described in the following paragraph.
  • the composition may be in the form of a thin layer or film, not necessarily requiring a backing layer.
  • a thin layer or film will possess sufficient flexibility and coherence, so that it may be produced in rolls or sheets, from which portions may be cut to a desired size. It is contemplated that such a layer may be transparent, so that the progress of therapeutic action may be observed, and also that it may be molded against the skin surface.
  • the composition when utilizing a tacky carrier, the composition will self-adhere to the locus under treatment. At the termination of treatment, the area of skin application may be washed to remove residual water-soluble polymer.
  • compositions may be applied for similar purposes as described e.g. in U.S. 4,524,065, it is believed to be self-evident that the present invention possesses marked advantages over the method of this U.S. Patent, in that, for example, it provides the possibility of treating a broad area of the skin at one time, contrasted with injection which depends on questionable diffusion from the injected site. Moreover, the requirement for repeated injections in U.S. 4,524,065 would place a strain on patient compliance, which is much less likely to arise in the present method. While particular embodiments of the invention have been particularly described above, it will be apparent to skilled persons that the present invention is not limited thereto, since many modifications or variations can be made within the scope of the claims which follow.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte à l'utilisation d'au moins un enzyme sélectionné parmi la collagénase et l'hyaluronidase, en association à au moins une composition porteuse, soluble dans l'eau, qui contient au moins un polymère biocompatible soluble dans l'eau froide, pour la fabrication d'un pansement destiné à l'application topique et comportant ladite composition sous forme de couche ou de film aux fins de la libération lente dudit enzyme. Ledit pansement présente une souplesse et une consistance suffisante, de sorte qu'il peut être produit sous forme de rouleaux ou de feuilles. La composition de cette invention peut être également utilisée sous forme de pansements prédécoupés comprenant une couche absorbante (4) supportant une fine couche (6) de ladite composition et tout à la fois collée à une couche de support non absorbante (2) et recouverte d'une fine couche pelable (8).
PCT/IL1999/000629 1998-11-23 1999-11-22 Traitement enzymatique et prevention des hypertrophies cutanees WO2000030578A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99956303A EP1152723A1 (fr) 1998-11-23 1999-11-22 Traitement enzymatique et prevention des hypertrophies cutanees
JP2000583463A JP2003517448A (ja) 1998-11-23 1999-11-22 肥厚性皮膚の酵素による処置および予防
AU12934/00A AU1293400A (en) 1998-11-23 1999-11-22 Enzymatic treatment and prevention of hypertrophic skin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12720998A IL127209A0 (en) 1998-11-23 1998-11-23 Composition and method for treatment of hypertrophic skin accumulations and their prevention
IL127209 1998-11-23

Publications (1)

Publication Number Publication Date
WO2000030578A1 true WO2000030578A1 (fr) 2000-06-02

Family

ID=11072176

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL1999/000629 WO2000030578A1 (fr) 1998-11-23 1999-11-22 Traitement enzymatique et prevention des hypertrophies cutanees

Country Status (6)

Country Link
EP (1) EP1152723A1 (fr)
JP (1) JP2003517448A (fr)
AU (1) AU1293400A (fr)
GB (1) GB2343844B (fr)
IL (1) IL127209A0 (fr)
WO (1) WO2000030578A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002091966A1 (fr) * 2001-05-11 2002-11-21 Kava Pharmaceuticals, Inc. Compositions de kavalactone et leurs methodes d'utilisation
EP1676559A2 (fr) * 2005-01-03 2006-07-05 L'oreal Article cosmétique ou dermatologique comportant un support soluble dans l'eau
EP1706094A2 (fr) * 2003-12-19 2006-10-04 Osio Corp. Traitement de conditions ophtalmologiques
US7879942B2 (en) 2006-10-05 2011-02-01 Eastman Chemical Company Switchable adhesive article for attachment to skin and method of using the same
US9086580B2 (en) 2012-08-10 2015-07-21 Osio Corporation Contact lens use in the treatment of an ophthalmologic condition
WO2023023776A1 (fr) * 2021-08-25 2023-03-02 Foothill Saddleback Pty Ltd Modificateur de tissu et ses utilisations

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10221194B4 (de) * 2002-05-13 2005-02-10 Fryda, Waltraud, Dr.med. Hyaluronidasehaltiges Hautpflegemittel
EP4134149A1 (fr) * 2021-08-11 2023-02-15 Lenzing Aktiengesellschaft Masque facial comportant une couche de support

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4154823A (en) * 1976-06-10 1979-05-15 Schutt Steven R Skin treatment compositions and methods of using same
US5409703A (en) * 1993-06-24 1995-04-25 Carrington Laboratories, Inc. Dried hydrogel from hydrophilic-hygroscopic polymer
US5516673A (en) * 1993-02-15 1996-05-14 Bar Ilan University Bioactive conjugates of cellulose with amino compounds
US5552162A (en) * 1993-02-09 1996-09-03 Arch Development Corporation Method for improvement of scar size and appearance
US5791352A (en) * 1996-06-19 1998-08-11 Fusion Medical Technologies, Inc. Methods and compositions for inhibiting tissue adhesion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB792544A (en) * 1956-05-07 1958-03-26 American Home Prod Therapeutic composition
AU568626B2 (en) * 1983-01-05 1988-01-07 Institut Pasteur Preparation having a high collagenolytic activity and pharmaceutical compositions containing it
FR2558171B1 (fr) * 1984-01-12 1986-08-01 Oreal Materiau polymerique a action enzymatique, son procede de preparation et son utilisation en tant que medicament
EP0162007A1 (fr) * 1984-04-18 1985-11-21 Geriaco AG Préparation stable et conservable d'insuline pour le traitement de l'acné vulgaris
US4784653A (en) * 1987-06-22 1988-11-15 Johnson & Johnson Patient Care, Inc. Absorbent adhesive dressing
US5393792A (en) * 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
DE19503338C2 (de) * 1995-02-02 1998-07-30 Lohmann Therapie Syst Lts Arzneiform zur Abgabe von Kollagenase an Wunden und Verfahren zu ihrer Herstellung und ihre Verwendung
IT1276684B1 (it) * 1995-06-08 1997-11-03 Bioextech Inc Formulazioni idrosolubili di collagenasi stabilizzata e procedimento per la loro preparazione
DE19627232A1 (de) * 1996-07-05 1998-01-08 Basf Ag Definierte Enzymmischungen für kosmetische Zwecke

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4154823A (en) * 1976-06-10 1979-05-15 Schutt Steven R Skin treatment compositions and methods of using same
US5552162A (en) * 1993-02-09 1996-09-03 Arch Development Corporation Method for improvement of scar size and appearance
US5516673A (en) * 1993-02-15 1996-05-14 Bar Ilan University Bioactive conjugates of cellulose with amino compounds
US5409703A (en) * 1993-06-24 1995-04-25 Carrington Laboratories, Inc. Dried hydrogel from hydrophilic-hygroscopic polymer
US5791352A (en) * 1996-06-19 1998-08-11 Fusion Medical Technologies, Inc. Methods and compositions for inhibiting tissue adhesion

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002091966A1 (fr) * 2001-05-11 2002-11-21 Kava Pharmaceuticals, Inc. Compositions de kavalactone et leurs methodes d'utilisation
US8679521B2 (en) 2003-12-19 2014-03-25 Osio Corporation Treatment of ophthalmic conditions
US9566317B2 (en) 2003-12-19 2017-02-14 Osio Corporation Treatment of ophthalmic conditions
US8877228B2 (en) 2003-12-19 2014-11-04 Osio Corporation Treatment of ophthalmic conditions
EP1706094A2 (fr) * 2003-12-19 2006-10-04 Osio Corp. Traitement de conditions ophtalmologiques
US9931382B2 (en) 2003-12-19 2018-04-03 Osio Corporation Treatment of ophthalmic conditions
EP1706094A4 (fr) * 2003-12-19 2012-03-28 Osio Corp Traitement de conditions ophtalmologiques
US8475831B2 (en) 2003-12-19 2013-07-02 Osio Corporation Treatment of ophthalmic conditions
US9241980B2 (en) 2003-12-19 2016-01-26 Osio Corporation Treatment of ophthalmic conditions
EP1676559A3 (fr) * 2005-01-03 2006-09-13 L'oreal Article cosmétique ou dermatologique comportant un support soluble dans l'eau
FR2880262A1 (fr) * 2005-01-03 2006-07-07 Oreal Article cosmetique ou dermatologique comportant un support soluble dans l'eau
EP1676559A2 (fr) * 2005-01-03 2006-07-05 L'oreal Article cosmétique ou dermatologique comportant un support soluble dans l'eau
US7879942B2 (en) 2006-10-05 2011-02-01 Eastman Chemical Company Switchable adhesive article for attachment to skin and method of using the same
US9086580B2 (en) 2012-08-10 2015-07-21 Osio Corporation Contact lens use in the treatment of an ophthalmologic condition
US10254564B2 (en) 2012-08-10 2019-04-09 Osio Corporation Contact lens use in the treatment of an ophthalmologic condition
US10969609B2 (en) 2012-08-10 2021-04-06 Osio Corporation Contact lens use in the treatment of an ophthalmologic condition
WO2023023776A1 (fr) * 2021-08-25 2023-03-02 Foothill Saddleback Pty Ltd Modificateur de tissu et ses utilisations
AU2022335159B2 (en) * 2021-08-25 2023-10-26 Foothill Saddleback Pty Ltd Tissue modifier and uses therefor

Also Published As

Publication number Publication date
GB2343844B (en) 2000-10-25
AU1293400A (en) 2000-06-13
GB9902711D0 (en) 1999-03-31
IL127209A0 (en) 1999-09-22
GB2343844A8 (en) 2000-06-14
JP2003517448A (ja) 2003-05-27
GB2343844A (en) 2000-05-24
EP1152723A1 (fr) 2001-11-14

Similar Documents

Publication Publication Date Title
Boateng et al. Wound healing dressings and drug delivery systems: a review
EP2337536B1 (fr) Pansement de plaie à couche d interface
US5206026A (en) Instantaneous delivery film
US6573249B2 (en) Topical wound therapeutic compositions
Chopra et al. Strategies and therapies for wound healing: a review
US6262020B1 (en) Topical wound therapeutic compositions
WO2014091288A1 (fr) Dispositif de collagène
JP2014513696A (ja) セアプローゼを含有する創傷デブリードマン組成物およびそれを用いた創傷治療の方法
CA3021485C (fr) Procedes de debridement de plaies chroniques
IL294659A (en) Methods and preparations of il2 skewed mutants
RU2106154C1 (ru) Перевязочный материал
Ballard et al. Developments in wound care for difficult to manage wounds
WO2000030578A1 (fr) Traitement enzymatique et prevention des hypertrophies cutanees
JP2005306746A (ja) 顔面用シワ治療剤
US11938173B2 (en) Use of Clostridium histolyticum protease mixture in promoting wound healing
RU2732224C2 (ru) Раноочищающая композиция для лечения ран
Chakravarthy Fabrication and evaluation of novel wound dressings and related biomaterials
IL212052A (en) An interlayer wound dressing bandage

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 12934

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 583463

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999956303

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999956303

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999956303

Country of ref document: EP